Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older Adults

Purpose

Semaglutide is a medication approved by the US Food and Drug Administration (FDA) as an antihyperglycemic (a drug that reduces glucoses in those with diabetes) and for weight management. This new study will help find out what effects, semaglutide has on people who take the drug and the drug's effect on physical function, body composition, and aging.

Conditions

  • Aging
  • Diabetes Mellitus, Type 2
  • PreDiabetes
  • Overweight and Obesity

Eligibility

Eligible Ages
Between 65 Years and 90 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Older than 65 - Have prediabetes or diabetes - BMI ≥ 27.0 kg/m2 - Living independently (not in assisted living or nursing home)

Exclusion Criteria

  • Have heart disease - Have liver disease - Smoke

Study Design

Phase
Phase 4
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Other
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Semaglutide and lifestyle intervention 		Participants will meet with a dietician throughout the study to discuss lifestyle counseling based on recommendation in the diabetes prevention program. They will also be given semaglutide for 20 weeks.
  • Drug: Semaglutide Injectable Product
    Semaglutide will be started at 0.25mg once a week for 4 weeks followed by 0.5mg once weekly for 4 weeks followed by 1.0mg once a week for 12 weeks.
    Other names:
    • Semaglutide and Lifestyle Counseling
  • Behavioral: Lifestyle Counseling
    Lifestyle Counseling will be provided throughout study intervention
Active Comparator
Lifestyle intervention 		Participants will meet with a dietician throughout the study to discuss lifestyle counseling based on recommendation in the diabetes prevention program
  • Behavioral: Lifestyle Counseling
    Lifestyle Counseling will be provided throughout study intervention

More Details

Status
Active, not recruiting
Sponsor
The University of Texas Health Science Center at San Antonio

Study Contact